The chemotherapy azacitidine (Vidaza®) has been approved
by the FDA for pediatric patients 1 month and older with newly diagnosed
juvenile myelomonocytic leukemia (JMML), an uncommon, aggressive,
and difficult to treat blood cancer. This JMML chemotherapy has the potential
to avoid using cytotoxic agents, which have short- and long-term serious side
effects on young patients.
Monday, July 11, 2022
The chemotherapy azacitidine (Vidaza®) has been approved by the FDA for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment